Serenatis Bio is a start-up biotech developing three novel drugs to treat obsessive-compulsive disorder (OCD), a common yet poorly treated and devastating mental illness with huge unmet need and commercial opportunity. Each drug has a different mechanism of action - targeting glutamate and dopamine receptors - using precision medicine to identify which OCD patients will respond to which drug.
Company Details
- Founded
- -
- Address
- Cambridge, Gb
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.serenatisbio.com
- HQ
- Cambridge
Serenatis Bio Questions
Serenatis Bio's website is http://www.serenatisbio.com
Serenatis Bio's LinkedIn profile is https://uk.linkedin.com/company/serenatis-bio
Serenatis Bio's industry is
Biotechnology Research
Serenatis Bio's top competitors are
Peripear Ltd,
Zonder,
Joey,
Sterling Bio Machines,
Gutsee Health,
Cellestial Health,
Cambridge Medixine Ltd.,
Novaterra,
P53,
Zinc.
Serenatis Bio's categories are Biotechnology Research
Serenatis Bio's founding year is 2024
